About COHERUS BIOSCIENCES, INC.
Coherus Oncology is focused on developing and commercializing next-generation immuno-oncology therapies to extend patient survival across tumor types. The company has FDA-approved therapy LOQTORZI® (toripalimab-tpzi) and multiple clinical-stage immuno-oncology candidates targeting the tumor microenvironment.
Developing and commercializing next-generation immuno-oncology therapiesAdvancing clinical-stage immuno-oncology candidates targeting the tumor microenvironmentStreamlined regulatory package development for drug approvalExpertise in immunology, oncology, manufacturing, and supply chain managementProven commercial and marketing capabilities
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to COHERUS BIOSCIENCES, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.